Dimerix (ASX:DXB) reported that the adult cohort of its ACTION3 Phase 3 kidney-disease trial was fully recruited at 333 patients. The company and its commercial partners chose to continue to the final proteinuria endpoint for a potential traditional US approval application, rather than seek an interim accelerated-approval route.

A Targeted Therapy for a Rare, Progressive Kidney Disease

DMX-200 is an investigational therapy for focal segmental glomerulosclerosis (FSGS), a kidney disease associated with protein loss in urine and declining kidney function. Dimerix is evaluating whether the treatment reduces proteinuria compared with placebo. A separate FSGS treatment received US approval in 2026, changing the therapeutic landscape.

ACTION3 Completes Recruitment

Dimerix reported that the adult ACTION3 cohort was fully recruited with 333 patients, while recruitment of adolescents continued separately. A prespecified 2024 interim futility analysis indicated DMX-200 was performing better than placebo on proteinuria at that point, but it did not establish the final trial result. The company reported seven independent safety reviews by April 2026 without a request to change the protocol.

Four Regional Licensing Partners

Dimerix reported four regional commercial partners for DMX-200, including Amicus Therapeutics in the US and other licensees in their respective territories. The company and its partners decided against an interim analysis for an accelerated-approval application and instead chose to pursue a traditional approval route if final proteinuria data support it.

What the Evidence Means

Completing adult recruitment enables follow-up and final analysis, but does not establish efficacy. Dimerix said the FDA considered the proteinuria endpoint suitable to support a traditional approval application if ACTION3 is positive. Regulatory approval and commercial outcomes remain contingent on the completed evidence and review.

Risks and Milestones Ahead

A negative or unclear final trial result would affect development plans. Follow-up through the planned treatment period, statistical interpretation, paediatric enrolment and regulatory review also present uncertainty. A newly approved FSGS treatment adds to the competitive context.

Readers should watch follow-up and final proteinuria data, paediatric recruitment, and any updated regulatory timetable. An accelerated-approval discussion should not be listed as the expected next step under the company’s April 2026 decision.